Sub-Saharan Africa in the scope of an increased burden of antiretroviral therapy related adverse effects

Apaperpublished today in贫穷的传染病讨论了撒哈拉以南非洲(SSA)国家的“测试和治疗”政策实施的挑战,并特别了解抗逆转录病毒疗法(ART)相关的不良反应。乔伯特·里奇·N·纳森(Jobert Richie N. Nansseu)在这里是一位作者,告诉我们更多。

该论文阐明了撒哈拉以南非洲(SSA)国家的严重缺乏准备和准备,以应对随之而来的与艺术相关的有毒和代谢并发症的负担增加,并强调迫切需要在SSA时填补空白。不要在不久的将来对“测试和治疗”政策的后果感到过分负担。

Chronic exposure to ART leads to serious medication-related adverse effects.

The positive change in the natural history of HIV/AIDS following the introduction and widespread use of continuous ART is no longer a topic of debate. Further, it has been clearly demonstrated that early ART initiation results in significant HIV transmission reduction, which is the rationale supporting the “test and treat” policy of the World Health Organization (WHO). As SSA is the epicenter of the HIV pandemic, it is believed that this region will benefit the most from this policy.

然而,长期接触会导致严重的艺术medication-related adverse effects. Therefore, it is anticipated that implementation of the WHO policy will lead to an exponential increase in ART-related adverse effects incidence and prevalence, especially in SSA where these conditions (such as cardiovascular disease, lipodystrophy, prediabetes and overt diabetes, insulin resistance and hyperlactatemia/lactic acidosis) are already getting to epidemic and alarming proportions.

In this context, SSA could be over-burdened subsequently to the “test and treat” implementation in the region. To know whether the region is yet ready and adequately prepared to cope with these challenges requires an up-to-date interrogation warranting an urgent examination so much so that the gaps could be rapidly identified and filled accordingly.

Most SSA countries are characterized by (extreme) poverty, very weak health systems, inadequate and low quality of health services, inaccessibility to existing health facilities, lack of (qualified) health personnel, lack of adequate equipment, inaccessibility and unaffordability of medicines, and heavy workload in a current context of cohabitation of infectious and non-communicable diseases.

Furthermore, there is dearth of data on the incidence and predictive factors of ART-related adverse effects in SSA, to anticipate on strategies that should be put in place to prevent the occurrence of these conditions or properly estimate the upcoming burden and prepare an adequate response plan.

SSA Governments, researchers and financial partners all together should come into play to work at identifying all the challenges related to the “test and treat’ policy implementation in the region and quickly address each of them so that implementation of such a policy does not aggravate the current burden of disease in SSA.

View the latest posts on the On Health homepage

注释